Boston Scientific acquires EMcision Ltd.

~Deal allows for wide scale distribution of EMcision's medical devices~

MONTREAL, March 5, 2018 /CNW Telbec/ - EMcision Ltd., a privately-held company headquartered in London, UK that develops and commercializes proprietary medical devices, today announced that it and its subsidiaries have been acquired by Boston Scientific (NYSE: BSX), the world's premier endoscopic devices company.

Founded by internationally renowned surgeon and inventor, Prof. Nagy Habib, EMcision develops innovative devices including the Habib^TM 4X, the Habib^TM EndoHPB and the Habib^TM EUS RFA. Those products have benefited close to 100,000 patients suffering from cancers of the liver, pancreas and bile ducts.

EMcision's flagship product, the Habib^TM EndoHPB, was the world's first endoscopic device for tumour ablation via ERCP using radiofrequency energy in patients with advanced and inoperable pancreatic cancer and cholangiocarcinoma.

"Recently, two randomised clinical trials showed independently a statistically significant survival advantage for patients treated with the Habib^TM EndoHPB," said Prof. Nagy Habib, EMcision's Chairman and founder. "This new treatment has empowered endoscopists with a very useful device for management of these unfortunate patients with advanced cancer."

EMcision devices are sold in 38 countries around the world and used by surgeons and endoscopists in most of the top US cancer centres such as MD Anderson, Memorial Sloan Kettering, Mayo Clinic, Cleveland Clinic, Johns Hopkins, Massachusetts General and Stanford.

"By partnering with Boston Scientific, we will continue delivering on our mission of improving the quality of life of cancer patients on a much larger scale. Boston Scientific has the resources and the know-how to further improve our technology, expand clinical indications and make it available to many more patients," said Cherif Habib, EMcision's outgoing CEO.

Boston Scientific, headquartered in Marlborough, Massachusetts, was founded in 1979 and employs over 27,000 people. Their products, across six business divisions, treat over 24 million patients every year.

About EMcision
EMcision was founded by internationally renowned surgeon and inventor of medical devices, Professor Nagy Habib, to develop proprietary medical devices based on proven RF technology for the surgical community. Devices for endoscopists and interventional radiologists soon followed. In 2002, EMcision developed the Habib™ 4X for the treatment of liver cancer, which has the reputation of being the #1 hepatic resection device in the U.S. The company combines scientific, commercial and management skills, brought together in a working partnership to develop and commercialize medical devices that are clinically relevant, cost-effective and enhance the quality of life of cancer patients. EMcision's R&D, engineering and commercialization operations are based in Montreal, and clinical activities are based at the Imperial College London and Hammersmith Hospital. To learn more, please visit www.emcision.com.

SOURCE EMcision International Inc.

For media inquiries: Adam Daifallah, 514.316.7089, [email protected]